Mesenchymal stem cells (MSCs), discovered and isolated from the bone marrow in the 1960s and with self-renewal capacity and multilineage differentiation potential, have valuable immunomodulatory abilities. Acute kidney injury (AKI) refers to rapid renal failure, which exhibits as quickly progressive decreasing excretion in few hours or days. This study was performed to assess the efficacy of MSCs in the treatment of AKI induced by ischemia-reperfusion using a meta-analysis method. A literature search using corresponding terms was performed in the following databases: Embase, Cochrane Library, PubMed, and ISI Web of Science databases up to Dec 31, 2019. Data for outcomes were identified, and the efficacy of MSCs for AKI was assessed using Cochrane Review Manager Version 5.3. Nineteen studies were eligible and recruited for this meta-analysis. MSC treatment can reduce the Scr levels at 1 day, 2 days, 3 days, 5 days, and >7 days (1 day: , 95% CI: -0.78, -0.34, ; 2 days: , 95% CI: -0.89, -0.28, ; 3 days: , 95% CI: -0.84, -0.45, ; 5 days: , 95% CI: -0.54, -0.16, ; and >7 days: , 95% CI: -0.36, -0.08, ) and can reduce the levels of BUN at 1 day, 2 days, 3 days, and 5 days (1 day: , 95% CI: -18.80, -4.64, ; 2 days: , 95% CI: -40.15, -27.05, ; 3 days: , 95% CI: -26.15, -16.14, ; and 5 days: , 95% CI: -11.06, -6.69, ), and it also can reduce the levels of proteinuria at 3 days and >7 days and alleviate the renal damage in animal models of AKI. In conclusion, MSCs might be a promising therapeutic agent for AKI induced by ischemia-reperfusion.

中文翻译：

---

间充质干细胞在动物模型中的缺血再灌注诱导的急性肾脏损伤治疗中的功效。

间充质干细胞（MSCs）在1960年代从骨髓中发现并分离出来，具有自我更新能力和多系分化潜能，具有重要的免疫调节能力。急性肾损伤（AKI）是指快速的肾衰竭，在数小时或数天内表现为快速进行性排泄减少。这项研究旨在通过荟萃分析评估MSC在缺血再灌注诱导的AKI治疗中的疗效。截至2019年12月31日，在以下数据库中使用相应术语进行了文献检索：Embase，Cochrane图书馆，PubMed和ISI Web of Science数据库。确定了结局数据，并使用Cochrane评估了MSC对AKI的疗效。查看管理器版本5.3。共有19项研究符合条件并被纳入该荟萃分析。， 95％CI：-0.78，-0.34，; 2天：， 95％CI：-0.89，-0.28，; 3天：， 95％CI：-0.84，-0.45，; 5天：， 95％CI：-0.54，-0.16，; 并且> 7天：， 95％CI：-0.36，-0.08，），并可以在1天，2天，3天和5天（1天：， 95％CI：-18.80，-4.64，; 2天：， 95％CI：-40.15，-27.05，; 3天：， 95％CI：-26.15，-16.14，; 和5天：， 95％CI：-11.06，-6.69，），还可以降低3天和> 7天时蛋白尿的水平，减轻AKI动物模型中的肾脏损害。总之，MSCs可能是缺血再灌注诱导的AKI的有希望的治疗剂。